Precigen, INC

Precigen announced robust second quarter 2026 financial results, highlighted by significant revenue growth from PAPZIMEOS and a notable shift to profitability.

Precigen stockholders approved an amendment to the 2023 Omnibus Incentive Plan to increase available shares by 7 million at the 2026 Annual Meeting.

Precigen announced strong first quarter 2026 financial results, driven by the successful launch of PAPZIMEOS, with net product revenue reaching $21.6 million and operations projected to reach cash flow break-even by year-end.

Precigen announced full year 2025 financial results, highlighting the successful US launch of PAPZIMEOS and a strategic path to cash flow break-even by the end of 2026.

Precigen, Inc. announced its third quarter 2025 financial results, highlighting the successful commercial launch of PAPZIMEOS for recurrent respiratory papillomatosis and a strengthened cash position despite a significant net loss increase driven by non-cash items.

Precigen, Inc. announced the conversion of $79 million in Series A Convertible Perpetual Preferred Stock into over 54.9 million shares of common stock.

Precigen Inc. announced its first-quarter 2026 financial results, showcasing a significant increase in product revenues driven by the commercial launch of Papzimeos.

Precigen reports significant Q3 2025 financial shifts, driven by the FDA approval of Papzimeos and a substantial increase in net loss due to warrant reclassification and preferred stock conversion.

Precigen reported a reduced net loss for the first half of 2025, driven by strategic pipeline prioritization and cost reductions, but faces substantial doubt about its ability to continue as a going concern without additional funding.

Precigen's Q1 2025 results reveal a net loss of $54.15 million and raise substantial doubt about its ability to continue as a going concern, despite FDA priority review for PRGN-2012.

Precigen, Inc. announced its third quarter 2024 results, highlighting a strategic shift towards its PRGN-2012 program and a reduction in workforce.

Precigen announced its Q2 2024 financial results and a strategic shift to prioritize the development of PRGN-2012, including a reduction in workforce and the shutdown of ActoBio operations.

Precigen achieved a significant milestone with full FDA approval for Papzimeos, its first commercial product for recurrent respiratory papillomatosis, as it navigates substantial financial losses and strategic pipeline adjustments.

Precigen files an amendment to its 2024 annual report to include information previously omitted from Part III, covering directors, executive officers, compensation, and corporate governance.

Precigen's 2024 10-K filing highlights a strategic shift towards PRGN-2012, financial uncertainties, and ongoing research and development efforts.

Precigen, Inc. has filed an amendment to its annual report on Form 10-K to include information previously omitted from Part III, related to directors, executive officers, and corporate governance.

Precigen's 2023 annual report highlights its advancements in gene and cell therapies while acknowledging substantial doubt about its ability to continue as a going concern due to ongoing losses.

Rutul R Shah, Chief Operating Officer of Precigen, Inc., sold 32,739 shares of common stock on August 6, 2026 for $6.86 per share.

Rutul R Shah, Chief Operating Officer of Precigen, Inc., sold 33,772 shares of common stock on August 3, 2026 for $6.50 per share.

Harry Thomasian Jr., Chief Financial Officer of Precigen, Inc., sold 100,000 shares of common stock on July 31, 2026 for $6.06 per share.

Precigen, Inc. CFO Harry Thomasian Jr. reported the sale of company stock under a pre-arranged trading plan.

Precigen, Inc. Chief Operating Officer Rutul R. Shah reported the sale of 42,924 shares of common stock under a pre-arranged 10b5-1 trading plan.

Precigen, Inc. (PGEN) President and CEO Helen Sabzevari sold 346,836 shares of common stock under a pre-arranged 10b5-1 trading plan.

Precigen, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Precigen is asking shareholders to vote on several key proposals at its 2025 Annual Meeting, including increasing authorized common stock, approving executive compensation, and amending incentive plans.

Precigen is asking shareholders to vote on key proposals at its upcoming annual meeting, including an amendment to its incentive plan, the election of directors, and executive compensation.

Randal J. Kirk and affiliated entities sold over 4.7 million shares of Precigen, Inc. common stock for approximately $15.5 million.

Entities controlled by Randal J. Kirk sold nearly 3 million shares of Precigen, Inc. common stock for approximately $12.3 million in open market transactions.

Randal J. Kirk and affiliated entities updated their beneficial ownership in Precigen, Inc., disclosing a significant conversion of preferred stock into common shares and a subsequent sale of common stock.

Several Merck-affiliated entities have jointly filed a Schedule 13G, reporting a combined 4.9% beneficial ownership of Precigen, Inc. common stock.

Point72 Asset Management and Steven A. Cohen have reported a 1.9% beneficial ownership stake in Precigen, Inc. as of March 31, 2026.

Patient Capital Management and Patient Opportunity Trust have increased their beneficial ownership in Precigen, Inc. to 10.18% and 7.8% respectively.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly reported a 5.2% beneficial ownership stake in Precigen, Inc.

Patient Capital Management, LLC and Patient Opportunity Trust have reported a combined beneficial ownership of 24.6% of Precigen, Inc.'s common stock.

The William H. Miller III Living Trust has reported a 9.2% beneficial ownership stake in Precigen, Inc., including shares from exercisable warrants.